The top analyst upgrades, downgrades and initiations seen on Wednesday include Amgen, Apple, Corning, Mobileye, Under Armour and Electronic Arts.
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some…
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
2017 could be different for the health care sector. It is very possible that this new administration could lead to more positive trials, FDA approvals, and mergers and acquisitions.
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
Tthe top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, American Express, American Water Works, Celgene and Square.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Amgen, Coca-Cola, IBM, Procter & Gamble, Viacom, SeaWorld and NovoCure.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
Now that the U.S. presidential election is over and Hillary Clinton is out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for…
The broad markets are holding steady near their double bottom set this summer. However, over the course of the past week this has been tested.
Though Amgen reported better-than-expected third-quarter results on Thursday, shares sank early Friday.
Chris Lange Biotech giant Amgen is scheduled to release its third-quarter financial results after the markets close on Thursday.
Chris Lange 
